Shuijuan Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shuijuan Shen has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Zhouhao Ren
School of Medicine, Shaoxing University, Shaoxing, P.R. China
4 shared publicationsJiaying Wu
Taizhou Central Hospital (Taizhou University Hospital)
3 shared publicationsJichao Guan
Department of Nephrology The First Affiliated Hospital of Shaoxing University, Shaoxing People's Hospital Shaoxing Zhejiang China
2 shared publicationsMengwei Zhang
Department of Nephrology, Shaoxing People’s Hospital (The First Affiliated Hospital, Shaoxing University), Shaoxing, P.R. China
2 shared publicationsMiaojia Ding
Department of Nephrology Shaoxing University School of Medicine Shaoxing Zhejiang China
2 shared publicationsShaorui Wu
Shaoxing University School of Medicine Shaoxing China
2 shared publications
Latest Publications
- Open Access
- 25 February 2026
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
A retrospective cohort study on the association between RAR and mortality in peritoneal Dialysis patients
Inflammation and malnutrition collectively constitute the dual challenge that predominantly shapes the prognosis of peritoneal dialysis (PD) patients. As a
- 25 February 2026
- Published by Springer Nature in BMC Nephrology
- Vol. 27 (1)
Open AccessA retrospective cohort study on the association between RAR and mortality in peritoneal Dialysis patients
Inflammation and malnutrition collectively constitute the dual challenge that predominantly shapes the prognosis of peritoneal dialysis (PD) patients. As a
- 30 July 2024
- Published by Wiley in Seminars in Dialysis
- Vol. 37 (5) , 404-407
Resolution of Peritoneal Dialysis‐Associated Peritonitis From Weissella confusa Combined Gastric Hookworm Disease: A Case Report and Literature Review
We reported a rare case of peritoneal dialysis‐associated peritonitis caused by Weissella confusa. In this case, the symptoms of peritonitis were insidious and atypical, with only turbid peritoneal dialysis effluent and no fever or abdominal pain. The peritoneal dialysis effluent showed slightly elevated leukocytes (predominantly lymphocytes). Weissella confusa was confirmed through repeated peritoneal dialysis effluent cultures. Gastroscopy revealed erosive gastritis with a hookworm infection. The patient recovered after antibiotic and deworming treatments. Our report highlights the unusual and atypical symptoms, characterized by insidious onset, turbid peritoneal dialysis fluid, and an absence of typical signs such as fever or abdominal pain.
- 30 July 2024
- Published by Wiley in Seminars in Dialysis
- Vol. 37 (5) , 404-407
Resolution of Peritoneal Dialysis‐Associated Peritonitis From Weissella confusa Combined Gastric Hookworm Disease: A Case Report and Literature Review
We reported a rare case of peritoneal dialysis‐associated peritonitis caused by Weissella confusa. In this case, the symptoms of peritonitis were insidious and atypical, with only turbid peritoneal dialysis effluent and no fever or abdominal pain. The peritoneal dialysis effluent showed slightly elevated leukocytes (predominantly lymphocytes). Weissella confusa was confirmed through repeated peritoneal dialysis effluent cultures. Gastroscopy revealed erosive gastritis with a hookworm infection. The patient recovered after antibiotic and deworming treatments. Our report highlights the unusual and atypical symptoms, characterized by insidious onset, turbid peritoneal dialysis fluid, and an absence of typical signs such as fever or abdominal pain.
- Open Access
- 25 June 2024
- Published by Springer Nature in BMC Nephrology
- Vol. 25 (1) , 1-9
The advanced lung cancer inflammation index is associated with mortality in peritoneal dialysis patients
Background: There is still a very high morbidity and mortality rate for patients undergoing peritoneal dialysis (PD). The advanced lung cancer inflammation index (ALI) has been demonstrated to be associated with the prognosis in multiple types of cancers. Like in cancer, systemic chronic low-grade inflammation is one of the distinguishing features of PD patients. Therefore, we aimed to investigate the relationships between the ALI and all-cause and cardiovascular disease (CVD) mortality in PD patients. Methods: Patients who started PD at Shaoxing People’s Hospital between 1 January 2013 and 31 December 2020 (n = 277) were recruited and followed up until 1 July 2023. They were divided into high-ALI group and low-ALI group according to the median of ALI. Kaplan–Meier curves and multivariate Cox regression analyses were used to assess the associations between the ALI and all-cause and CVD mortality. Receiver operating characteristic (ROC) curves were constructed, and the area under the curve (AUC) was calculated to determine the predictive power of the ALI for all- cause and CVD mortality. Results: During the median follow-up of 40.50 months (interquartile range, 26.42–59.77 months), a total of 55 patients died, 31 of whom died due to CVD. Kaplan–Meier curves revealed that patients in the low-ALI group had significantly lower cumulative and cardiovascular cumulative survival rates than did those in the high-ALI group (all P < 0.001). After we corrected for confounders, the risk of all-cause and CVD mortality was significantly greater in the low-ALI group than in the high-ALI group [hazard ratio (HR) 1.944, 95% confidence interval (CI) 1.068–3.540, P = 0.030, and HR 2.672, 95% CI 1.188–6.009, P = 0.017, respectively]. The predictive value of ALI (AUC = 0.708, 95% CI 0.630–0.786, P < 0.001) for all-cause mortality was superior to albumin (AUC = 0.644, 95% CI 0.556–0.726, P < 0.001), body mass index (AUC = 0.581, 95% CI 0.496–0.659, P = 0.069) and neutrophil-to-lymphocyte ratio (AUC = 0.675, 95% CI 0.596–0.754, P < 0.001). Conclusion: A lower ALI is an independent risk factor for all-cause and cardiovascular mortality in PD patients. The ALI may be an effective indicator for predicting outcomes in PD patients.
- 25 June 2024
- Published by Springer Nature in BMC Nephrology
- Vol. 25 (1) , 1-9
Open AccessThe advanced lung cancer inflammation index is associated with mortality in peritoneal dialysis patients
Background: There is still a very high morbidity and mortality rate for patients undergoing peritoneal dialysis (PD). The advanced lung cancer inflammation index (ALI) has been demonstrated to be associated with the prognosis in multiple types of cancers. Like in cancer, systemic chronic low-grade inflammation is one of the distinguishing features of PD patients. Therefore, we aimed to investigate the relationships between the ALI and all-cause and cardiovascular disease (CVD) mortality in PD patients. Methods: Patients who started PD at Shaoxing People’s Hospital between 1 January 2013 and 31 December 2020 (n = 277) were recruited and followed up until 1 July 2023. They were divided into high-ALI group and low-ALI group according to the median of ALI. Kaplan–Meier curves and multivariate Cox regression analyses were used to assess the associations between the ALI and all-cause and CVD mortality. Receiver operating characteristic (ROC) curves were constructed, and the area under the curve (AUC) was calculated to determine the predictive power of the ALI for all- cause and CVD mortality. Results: During the median follow-up of 40.50 months (interquartile range, 26.42–59.77 months), a total of 55 patients died, 31 of whom died due to CVD. Kaplan–Meier curves revealed that patients in the low-ALI group had significantly lower cumulative and cardiovascular cumulative survival rates than did those in the high-ALI group (all P < 0.001). After we corrected for confounders, the risk of all-cause and CVD mortality was significantly greater in the low-ALI group than in the high-ALI group [hazard ratio (HR) 1.944, 95% confidence interval (CI) 1.068–3.540, P = 0.030, and HR 2.672, 95% CI 1.188–6.009, P = 0.017, respectively]. The predictive value of ALI (AUC = 0.708, 95% CI 0.630–0.786, P < 0.001) for all-cause mortality was superior to albumin (AUC = 0.644, 95% CI 0.556–0.726, P < 0.001), body mass index (AUC = 0.581, 95% CI 0.496–0.659, P = 0.069) and neutrophil-to-lymphocyte ratio (AUC = 0.675, 95% CI 0.596–0.754, P < 0.001). Conclusion: A lower ALI is an independent risk factor for all-cause and cardiovascular mortality in PD patients. The ALI may be an effective indicator for predicting outcomes in PD patients.
- Open Access
- 26 September 2023
- Published by Springer Nature in Research Square
Advanced lung cancer inflammation index is associated with mortality in peritoneal dialysis patients
Background There is still a very high morbidity and mortality rate for patients undergoing peritoneal dialysis (PD). The advanced lung cancer inflammation index (ALI) has been demonstrated to be associated with prognosis in multiple types of cancers. Similar to cancer, systemic chronic low-grade inflammation is one of the distinguishing features of PD patients. Therefore, we aimed to investigate the relationship between ALI and all-cause and cardiovascular mortality in PD patients. Methods 277 patients who started PD at Shaoxing People's Hospital between 1 January 2013 and 31 December 2020 were recruited and followed up until 1 July 2023. The dose-response relationship between ALI and mortality was described by restricted cubic splines. Receiver operating characteristic (ROC) analysis was performed and the area under the curve (AUC) was calculated to determine the predictive power of ALI for all- cause mortality and CVD mortality. Kaplan-Meier curves and multivariate cox regression analyses were used to assess the association between ALI and all-cause mortality and cardiovascular mortality. Result During the median follow-up of 40.50 months (interquartile range, 26.42~59.77 months), a total of 55 patients died and 31 of them died due to cardiovascular disease. Kaplan-Meier curves showed that patients in the low ALI group had significantly lower cumulative survival rate and cardiovascular cumulative survival rate than those in the high ALI group (all P < 0.001). After correcting for confounders, the risk of all-cause mortality and cardiovascular death was significantly higher in the low ALI group than in the high ALI group [hazard ratio (HR) 1.944, 95% confidence interval (Cl) 1.068~3.540, P = 0.030, and HR 2.672, 95% Cl 1.188~6.009, P = 0.017, respectively]. Conclusion A lower ALI is an independent risk factor for all-cause mortality and cardiovascular mortality in PD patients. ALI may be an effective indicator for predicting outcomes in PD patients.
- 26 September 2023
- Published by Springer Nature in Research Square
Open AccessAdvanced lung cancer inflammation index is associated with mortality in peritoneal dialysis patients
Background There is still a very high morbidity and mortality rate for patients undergoing peritoneal dialysis (PD). The advanced lung cancer inflammation index (ALI) has been demonstrated to be associated with prognosis in multiple types of cancers. Similar to cancer, systemic chronic low-grade inflammation is one of the distinguishing features of PD patients. Therefore, we aimed to investigate the relationship between ALI and all-cause and cardiovascular mortality in PD patients. Methods 277 patients who started PD at Shaoxing People's Hospital between 1 January 2013 and 31 December 2020 were recruited and followed up until 1 July 2023. The dose-response relationship between ALI and mortality was described by restricted cubic splines. Receiver operating characteristic (ROC) analysis was performed and the area under the curve (AUC) was calculated to determine the predictive power of ALI for all- cause mortality and CVD mortality. Kaplan-Meier curves and multivariate cox regression analyses were used to assess the association between ALI and all-cause mortality and cardiovascular mortality. Result During the median follow-up of 40.50 months (interquartile range, 26.42~59.77 months), a total of 55 patients died and 31 of them died due to cardiovascular disease. Kaplan-Meier curves showed that patients in the low ALI group had significantly lower cumulative survival rate and cardiovascular cumulative survival rate than those in the high ALI group (all P < 0.001). After correcting for confounders, the risk of all-cause mortality and cardiovascular death was significantly higher in the low ALI group than in the high ALI group [hazard ratio (HR) 1.944, 95% confidence interval (Cl) 1.068~3.540, P = 0.030, and HR 2.672, 95% Cl 1.188~6.009, P = 0.017, respectively]. Conclusion A lower ALI is an independent risk factor for all-cause mortality and cardiovascular mortality in PD patients. ALI may be an effective indicator for predicting outcomes in PD patients.
- 8 March 2023
- Published by Wiley in Seminars in Dialysis
- Vol. 36 (5) , 390-398
Prediction of the sarcopenia in peritoneal dialysis using simple clinical information: A machine learning‐based model
Introduction: Sarcopenia is associated with significant cardiovascular risk, and death in patients undergoing peritoneal dialysis (PD). Three tools are used for diagnosing sarcopenia. The evaluation of muscle mass requires dual energy X‐ray absorptiometry (DXA) or computed tomography (CT), which is labor‐intensive and relatively expensive. This study aimed to use simple clinical information to develop a machine learning (ML)‐based prediction model of PD sarcopenia.Methods: According to the newly revised Asian Working Group for Sarcopenia (AWGS2019), patients were subjected to complete sarcopenia screening, including appendicular skeletal muscle mass, grip strength, and five‐time chair stand time test. Simple clinical information such as general information, dialysis‐related indices, irisin and other laboratory indices, and bioelectrical impedance analysis (BIA) data were collected. All data were randomly split into training (70%) and testing (30%) sets. Difference, correlation, univariate, and multivariate analyses were used to identify core features significantly associated with PD sarcopenia.Result: 12 core features (C), namely, grip strength, body mass index (BMI), total body water value, irisin, extracellular water/total body water, fat‐free mass index, phase angle, albumin/globulin, blood phosphorus, total cholesterol, triglyceride, and prealbumin were excavated for model construction. Two ML models, the neural network (NN), and support vector machine (SVM) were selected with tenfold cross‐validation to determine the optimal parameter. The C‐SVM model showed a higher area under the curve (AUC) of 0.82 (95% confidence interval [CI]: 0.67–1.00), with a highest specificity of 0.96, sensitivity of 0.91, positive predictive value (PPV) of 0.96, and negative predictive value (NPV) of 0.91.Conclusion: The ML model effectively predicted PD sarcopenia and has clinical potential to be used as a convenient sarcopenia screening tool.
- 8 March 2023
- Published by Wiley in Seminars in Dialysis
- Vol. 36 (5) , 390-398
Prediction of the sarcopenia in peritoneal dialysis using simple clinical information: A machine learning‐based model
Introduction: Sarcopenia is associated with significant cardiovascular risk, and death in patients undergoing peritoneal dialysis (PD). Three tools are used for diagnosing sarcopenia. The evaluation of muscle mass requires dual energy X‐ray absorptiometry (DXA) or computed tomography (CT), which is labor‐intensive and relatively expensive. This study aimed to use simple clinical information to develop a machine learning (ML)‐based prediction model of PD sarcopenia.Methods: According to the newly revised Asian Working Group for Sarcopenia (AWGS2019), patients were subjected to complete sarcopenia screening, including appendicular skeletal muscle mass, grip strength, and five‐time chair stand time test. Simple clinical information such as general information, dialysis‐related indices, irisin and other laboratory indices, and bioelectrical impedance analysis (BIA) data were collected. All data were randomly split into training (70%) and testing (30%) sets. Difference, correlation, univariate, and multivariate analyses were used to identify core features significantly associated with PD sarcopenia.Result: 12 core features (C), namely, grip strength, body mass index (BMI), total body water value, irisin, extracellular water/total body water, fat‐free mass index, phase angle, albumin/globulin, blood phosphorus, total cholesterol, triglyceride, and prealbumin were excavated for model construction. Two ML models, the neural network (NN), and support vector machine (SVM) were selected with tenfold cross‐validation to determine the optimal parameter. The C‐SVM model showed a higher area under the curve (AUC) of 0.82 (95% confidence interval [CI]: 0.67–1.00), with a highest specificity of 0.96, sensitivity of 0.91, positive predictive value (PPV) of 0.96, and negative predictive value (NPV) of 0.91.Conclusion: The ML model effectively predicted PD sarcopenia and has clinical potential to be used as a convenient sarcopenia screening tool.
- 1 February 2023
- Published by JLE in Nephrologie & Therapeutique
- Vol. 19 (1) , 66-75
Prediction of sarcopenia among peritoneal dialysis patients using a combination of irisin and phase angle
Sarcopenia is associated with significant morbidity and mortality in patients undergoing peritoneal dialysis (PD). Three different tools must be applied to measure the three indices for diagnosing sarcopenia. Considering the cumbersome diagnostic steps and multi-layered mechanisms underlying sarcopenia, we combined new biomarker with bioelectrical impedance analysis (BIA) data to predict PD sarcopenia. Patients underwent regular PD were asked to complete sarcopenia screening, including appendicular skeletal muscle mass, handgrip strength, and the 5-time chair stand time test according to the newly revised diagnosis consensus of Asian Working Group for Sarcopenia (AWGS2019). Serum was collected for centralized detection of the irisin levels. BIA data, especially the phase angle (PhA), as well as patient's general clinical information, dialysis related indices, laboratory data and body composition data were recorded. Among 105 enrolled PD patients (41.0% men, mean age 54.2 ± 8.89 years), the sarcopenia prevalence was 31.4% and the sarcopenic obesity was 8.6%. Binary regression analysis showed that serum irisin concentrations (OR = 0.98; 95% CI,0.97-0.99; p = 0.002), PhA (OR = 0.43; 95% CI, 0.21-0.90; p = 0.025) and body mass index (BMI) (OR = 0.64; 95% CI, 0.49-0.83; p = 0.001) were independently associated with PD sarcopenia. The AUC of the combination use of serum irisin concentrations and PhA for predicting PD sarcopenia was 0.925 with a sensitivity of 100% and specificity of 84.0% in male and was 0.880 with a sensitivity of 92.0% and specificity of 81.5% in female. PD sarcopenia score=1533.48+-0.75*Handgrip strength+4.63*BMI+-18.07*Total body water +-11.87*Extra-cellular water / total body water +9.26*Fat free mass index+-83.41*PhA+22.42*Albumin/Globulin+-26.38*blood phosphorus+-17.04*Total cholesterol+-29.02*Triglyceride+-0.29*Prealbumin+-0.17*Irisin. Sarcopenia is relatively common among PD patients. The combination of serum irisin concentrations and PhA facilitated the rapid prediction of PD sarcopenia and could serve as an optimal screening tool for PD sarcopenia in clinical settings.
- 1 February 2023
- Published by JLE in Nephrologie & Therapeutique
- Vol. 19 (1) , 66-75
Prediction of sarcopenia among peritoneal dialysis patients using a combination of irisin and phase angle
Sarcopenia is associated with significant morbidity and mortality in patients undergoing peritoneal dialysis (PD). Three different tools must be applied to measure the three indices for diagnosing sarcopenia. Considering the cumbersome diagnostic steps and multi-layered mechanisms underlying sarcopenia, we combined new biomarker with bioelectrical impedance analysis (BIA) data to predict PD sarcopenia. Patients underwent regular PD were asked to complete sarcopenia screening, including appendicular skeletal muscle mass, handgrip strength, and the 5-time chair stand time test according to the newly revised diagnosis consensus of Asian Working Group for Sarcopenia (AWGS2019). Serum was collected for centralized detection of the irisin levels. BIA data, especially the phase angle (PhA), as well as patient's general clinical information, dialysis related indices, laboratory data and body composition data were recorded. Among 105 enrolled PD patients (41.0% men, mean age 54.2 ± 8.89 years), the sarcopenia prevalence was 31.4% and the sarcopenic obesity was 8.6%. Binary regression analysis showed that serum irisin concentrations (OR = 0.98; 95% CI,0.97-0.99; p = 0.002), PhA (OR = 0.43; 95% CI, 0.21-0.90; p = 0.025) and body mass index (BMI) (OR = 0.64; 95% CI, 0.49-0.83; p = 0.001) were independently associated with PD sarcopenia. The AUC of the combination use of serum irisin concentrations and PhA for predicting PD sarcopenia was 0.925 with a sensitivity of 100% and specificity of 84.0% in male and was 0.880 with a sensitivity of 92.0% and specificity of 81.5% in female. PD sarcopenia score=1533.48+-0.75*Handgrip strength+4.63*BMI+-18.07*Total body water +-11.87*Extra-cellular water / total body water +9.26*Fat free mass index+-83.41*PhA+22.42*Albumin/Globulin+-26.38*blood phosphorus+-17.04*Total cholesterol+-29.02*Triglyceride+-0.29*Prealbumin+-0.17*Irisin. Sarcopenia is relatively common among PD patients. The combination of serum irisin concentrations and PhA facilitated the rapid prediction of PD sarcopenia and could serve as an optimal screening tool for PD sarcopenia in clinical settings.
- Open Access
- 23 July 2022
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 36 (9)
Establishment of a time‐resolved immunoassay for acute kidney injury based on the detection of Kim‐1
Aim: To establish a highly sensitive time‐resolved fluorescence immunoassay (TRFIA) of kidney injury molecule‐1 (Kim‐1) and evaluate its clinical value in acute kidney injury (AKI).Methods: The Kim‐1‐TRFIA was established by the double‐antibody sandwich method, and the method was evaluated. The established Kim‐1‐TRFIA was used to detect the concentration of Kim‐1 in the serum of healthy controls and patients with AKI.Results: The optimal coating antibody concentration and optimal Eu3+‐labeled antibody dilution ratio for Kim‐1‐TRFIA are 1 μg/ml and 1:140, respectively. The linear range is 42.71–4666.69 pg/ml. The intra‐ and inter‐assay coefficients of variation are p < 0.001). Staging patients with AKI by glomerular filtration rate shows that the serum concentration of Kim‐1 increases significantly with increasing disease severity (p < 0.05).Conclusion: A highly sensitive Kim‐1‐TRFIA was established. With this immunoassay, a good differential diagnosis can be made, and healthy people and AKI patients can be differentiated by detecting the concentration of Kim‐1 in the serum. Moreover, the severity of AKI patients can be determined.
- 23 July 2022
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 36 (9)
Open AccessEstablishment of a time‐resolved immunoassay for acute kidney injury based on the detection of Kim‐1
Aim: To establish a highly sensitive time‐resolved fluorescence immunoassay (TRFIA) of kidney injury molecule‐1 (Kim‐1) and evaluate its clinical value in acute kidney injury (AKI).Methods: The Kim‐1‐TRFIA was established by the double‐antibody sandwich method, and the method was evaluated. The established Kim‐1‐TRFIA was used to detect the concentration of Kim‐1 in the serum of healthy controls and patients with AKI.Results: The optimal coating antibody concentration and optimal Eu3+‐labeled antibody dilution ratio for Kim‐1‐TRFIA are 1 μg/ml and 1:140, respectively. The linear range is 42.71–4666.69 pg/ml. The intra‐ and inter‐assay coefficients of variation are p < 0.001). Staging patients with AKI by glomerular filtration rate shows that the serum concentration of Kim‐1 increases significantly with increasing disease severity (p < 0.05).Conclusion: A highly sensitive Kim‐1‐TRFIA was established. With this immunoassay, a good differential diagnosis can be made, and healthy people and AKI patients can be differentiated by detecting the concentration of Kim‐1 in the serum. Moreover, the severity of AKI patients can be determined.